US & Europe · Independent Updated August 2026
The Banned in Europe Registry
Explainers

The Lash Serum Loophole: How a Glaucoma Drug Ended Up in Your Beauty Routine

Europe just declared the ingredient behind those miracle lash serums unsafe for cosmetics. The US has known it acts like a drug since 2011. Here's why the same molecule is a prescription in one aisle and a $60 beauty splurge in another.

By 8 min read Explainers

If you’ve ever bought a lash serum that actually worked, you probably remember the small thrill of it. Two months in, the lashes are longer, darker, genuinely different. That result is real. And it should give you pause, because a cosmetic isn’t supposed to do that. When a product changes your body that dramatically, it usually means you’re not using a cosmetic at all. You’re using a drug that’s been dressed up as one.

That’s the whole story of prostaglandin lash serums, and in early 2026 Europe said so out loud. Its top cosmetics science panel ruled that the ingredients making these serums work can’t be considered safe for cosmetic use. The US figured out the same thing back in 2011, sent a warning letter, and then, in a very American way, mostly let the market keep going. The result is one of the cleaner examples of a regulatory gap you’ll find: the same class of molecule is a controlled prescription in one aisle and a self-serve beauty purchase in the next.

Let me walk through what’s actually happening on your lash line.

Why these serums work: they’re borrowing a glaucoma drug

The active ingredients in the serums that really move the needle belong to a family called prostaglandin analogues. The names are a mouthful: bimatoprost, isopropyl cloprostenate (often shortened to ICP), and a longer one usually abbreviated DDDE. What they share is a mechanism. They bind to the same receptor in your body, the prostaglandin FP receptor, that a class of glaucoma medications targets.

Here’s the origin story, and it’s a good one. Ophthalmologists prescribing prostaglandin eye drops for glaucoma, drugs like Lumigan, kept noticing a side effect: their patients’ eyelashes were growing longer and thicker. Allergan took that side effect and turned it into a product. Latisse, the prescription eyelash drug, was approved by the FDA in 2008, and its active ingredient, bimatoprost, is the exact same molecule sold as a glaucoma treatment. Same drug, different label.

So the science is settled on one point: these molecules genuinely grow lashes. The question was never whether they work. It’s what else they do, and who should be allowed to sell them.

What the FDA said, and when

The US actually caught this early. In April 2011 the FDA sent a warning letter to the maker of RapidLash and several private-label lash serums. The agency’s logic was clean: isopropyl cloprostenate is a synthetic prostaglandin analogue in the same class as the active ingredient in FDA-approved drugs. A product built around it, making claims about growing lashes, is an unapproved new drug, not a cosmetic. The letter listed the ocular risks the agency was worried about, including eye irritation, redness, changes in iris color, and macular edema.

That warning letter is fifteen years old now. And here’s the honest part: it didn’t clear the market. Lash serums with prostaglandin analogues have kept selling in the US, sometimes labeled as cosmetics, sometimes with the active ingredient buried under an unfamiliar chemical name on the back of the box. The FDA’s warning-letter approach handles specific companies making specific claims. It doesn’t function like a clean, categorical ban. Which is how you end up, a decade and a half later, with these ingredients still easy to buy.

What Europe just did

Europe took the categorical route, and it took it recently.

The EU’s Scientific Committee on Consumer Safety, the SCCS, is the panel that evaluates whether cosmetic ingredients are safe. In a final opinion adopted on 2 February 2026, the committee concluded that the prostaglandin analogues it examined, including isopropyl cloprostenate and DDDE, cannot be considered safe for use in cosmetic products meant to promote eyelash or eyebrow growth.

The reasoning is worth noting, because it isn’t a fear-mongering document. The SCCS emphasized that these are pharmacologically potent compounds that act even at very low concentrations, and it flagged uncertainty about systemic effects, not just local irritation. In other words, the committee’s problem wasn’t that the serums might sting. It was that a molecule this active, absorbed near your eye, is doing drug-level things to your body, and there wasn’t enough data to call that safe for unsupervised cosmetic use. The EU proposal on the table would add prostaglandins and their analogues as a broad prohibited entry to the cosmetics regulation. Canada, for what it’s worth, banned isopropyl cloprostenate from cosmetics back in 2019.

The side effects, told straight

This is where calibration matters, because the internet tends to swing between “totally fine, everyone uses it” and “you’ll go blind.” Neither is right. Here’s what the medical literature actually supports.

The most documented serious side effect is prostaglandin-associated periorbitopathy, or PAP. It’s a real, named condition, and the Latisse prescribing information lists it under postmarketing experience. Chronic use of these molecules can cause the fat pads around the eye to shrink, producing a hollowed, sunken look, deeper eyelid creases, and eyes that appear more deep-set. The unnerving part is that the effect can be subtle and slow, so people don’t always connect it to the serum they’ve been using nightly for a year. The reassuring part, and it’s genuine, is that published case reports show PAP is often partially or fully reversible once you stop.

The second one is iris darkening. Prostaglandin analogues can permanently increase the brown pigment in the iris, most noticeably in people with mixed-color eyes, hazel or green-brown. This change, unlike the fat loss, tends to be permanent. It’s well established from the glaucoma-drug literature, where the drops sit directly in the eye. For a lash serum applied to the lash line, the exposure is lower, but the mechanism is the same, and product can migrate.

Then there’s the everyday stuff: redness, irritation, itching, darkening of the eyelid skin. Common, usually mild, usually reversible.

So the honest summary is this. These serums are not going to blind you, and the catastrophic outcomes are rare. But they’re not cosmetics in any meaningful sense. They’re drugs with a real side-effect profile, and the serious ones, the sunken eyes and the permanently darker iris, are exactly the kind of thing you’d want a doctor watching for, which is the whole point of a prescription.

Why the same molecule lives in two different aisles

Step back and the transatlantic picture is clarifying.

In the US, if you want bimatoprost for your lashes, the “official” route is Latisse, a prescription you get from a doctor who can warn you about PAP and iris changes and check in on you. But right alongside it, you can buy an over-the-counter serum built on a chemical cousin, isopropyl cloprostenate, with no prescription, no consultation, and often no clear disclosure that it works the same way. The FDA considers those products unapproved drugs, but its enforcement is case-by-case, and the shelves stay stocked.

In Europe, the drug route exists too, through ophthalmology, but the cosmetic route is being closed off at the category level. The SCCS opinion doesn’t target one brand’s marketing claims. It says the ingredient class itself doesn’t belong in a cosmetic, which is a fundamentally different tool than a warning letter.

This is the pattern this site keeps running into, and it’s worth naming because it cuts against the usual narrative. The gap between Europe and America here isn’t really about which chemicals are “allowed.” Bimatoprost is a legal, approved drug in both places. The gap is about how each system handles a substance that sits on the border between cosmetic and drug. Europe tends to resolve that ambiguity by pulling the ingredient out of the cosmetic category entirely. America tends to leave it in the market and police the edges, one warning letter at a time.

If you’re a fan of your lash serum, none of this means you have to panic. It means you should know what you’re actually using. Check the ingredient list for anything ending in “-prost,” “-prostenate,” or “-prostamide.” If it’s there, you’re using a drug, and the smart move is a real conversation with an eye doctor, not a comment section. The lashes are real. So is everything else the molecule is doing.

Sources